ReviewInternational journal of cancer2008
Recent advances in strategies for immunotherapy of human papillomavirus-induced lesions.
Review in International journal of cancer, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 69 citations in OpenAlex.
- Review
- Investigation of the Optimal Prime Boost Spacing Regimen for a Cancer Therapeutic Vaccine Targeting Human Papillomavirus.Cancers · 2022Article
- Autologous cervical tumor lysate pulsed dendritic cell stimulation followed by cisplatin treatment abrogates FOXP3+ cells in vitro.Journal of gynecologic oncology · 2021Article
- Combining MPDL3280A with adoptive cell immunotherapy exerts better antitumor effects against cervical cancer.Bioengineered · 2017Article
- A prime/boost strategy using DNA/fowlpox recombinants expressing the genetically attenuated E6 protein as a putative vaccine against HPV-16-associated cancers.Journal of translational medicine · 2015Article
- Role of human papillomaviruses in carcinogenesis.Ecancermedicalscience · 2015Review
- Anti-tumor effects of genetic vaccines against HPV major oncogenes.Human vaccines & immunotherapeutics · 2015Article
- Therapeutic Vaccine Strategies against Human Papillomavirus.Vaccines · 2014Review
- Article
- Cytolytic activity of the human papillomavirus type 16 E711-20 epitope-specific cytotoxic T lymphocyte is enhanced by heat shock protein 110 in HLA-A*0201 transgenic mice.Clinical and vaccine immunology : CVI · 2013Article
- Induction of robust cellular immunity against HPV6 and HPV11 in mice by DNA vaccine encoding for E6/E7 antigen.Human vaccines & immunotherapeutics · 2012Article
- Perspective for prophylaxis and treatment of cervical cancer: an immunological approach.International reviews of immunology · 2012Review
- Virus-Like Particles Harboring CCL19, IL-2 and HPV16 E7 Elicit Protective T Cell Responses in HLA-A2 Transgenic Mice.The open virology journal · 2012Article
- Therapeutic Human Papillomavirus (HPV) Vaccines: A Novel Approach.The open virology journal · 2012Article
- Safety and Immunogenicity of a Human Papillomavirus Peptide Vaccine (CIGB-228) in Women with High-Grade Cervical Intraepithelial Neoplasia: First-in-Human, Proof-of-Concept Trial.ISRN obstetrics and gynecology · 2011Article
- Immunological and clinical effects of vaccines targeting p53-overexpressing malignancies.Journal of biomedicine & biotechnology · 2011Review
- Expression of LIGHT/TNFSF14 combined with vaccination against human papillomavirus Type 16 E7 induces significant tumor regression.Cancer research · 2010Article
- Naturally occurring systemic immune responses to HPV antigens do not predict regression of CIN2/3.Cancer immunology, immunotherapy : CII · 2010Article
- Fowlpox virus recombinants expressing HPV-16 E6 and E7 oncogenes for the therapy of cervical carcinoma elicit humoral and cell-mediated responses in rabbits.Journal of translational medicine · 2010Article
- Vaccines to prevent infections by oncoviruses.Annual review of microbiology · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Human papillomavirus (HPV)-induced lesions are distinct in that they have targetable foreign antigens, the expression of which is necessary to maintain the cancerous phenotype. Hence, they pose as a very attractive target for "proof of concept" studies in the development of therapeutic vaccines. This review will focus on the most recent clinical trials for the immunotherapy of mucosal and cutaneous HPV-induced lesions as well as emerging therapeutic strategies that have been tested in preclinical models for HPV-induced lesions. Progress in peptide-based vaccines, DNA-based vaccines, viral/bacterial vector-based vaccines, immune response modifiers, photodynamic therapy and T cell receptor based therapy for HPV will be discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.